Seeking Alpha

SPDR S&P Pharmaceuticals ETF (XPH)

  • Apr. 22, 2014, 12:14 PM
    | Apr. 22, 2014, 12:14 PM | Comment!
  • Dec. 14, 2011, 7:50 AM
    Fitch is establishing a negative 2012 outlook for pharmaceutical companies, arguing soft demand, patent expirations, and government spending cuts will take a toll on the industry; the patent expirations (I, II, III) are seen affecting LLY, BMY, and PFE the most. Fitch also sees pharmas responding to these challenges by stepping up their M&A activity.
    | Dec. 14, 2011, 7:50 AM | Comment!
XPH Description
The SPDR® S&P® Pharmaceuticals ETF seeks to replicate as closely as possible, before expenses, the total return performance of the S&P Pharmaceuticals Select Industry® Index. Our approach is designed to provide portfolios with low portfolio turnover, accurate tracking, and lower costs.
See more details on sponsor's website
Sector: Healthcare
Country: United States
Find the right ETFs for your portfolio: Visit Seeking Alpha's ETF Hub